Lipocalin-type prostaglandin D synthase is a powerful biomarker for severity of stable coronary artery disease

Teruo Inoue, Yutaka Eguchi, Tetsuya Matsumoto, Yoshiyuki Kijima, Yoji Kato, Yukio Ozaki, Katsuhisa Waseda, Hiroshi Oda, Kosuke Seiki, Koichi Node, Yoshihiro Urade

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

Lipocalin-type prostaglandin D synthase (L-PGDS), which is responsible for the biosynthesis of prostaglandin (PG) D2, has been found to be present in the atherosclerotic plaque of the human coronary artery and also to be detectable in human serum. This multicenter cooperative study was designed to establish the diagnostic value of measuring serum L-PGDS for coronary artery disease. The study included 1013 consecutive patients suspected of having stable coronary artery disease who underwent diagnostic coronary angiography. Peripheral blood was collected prior to angiography. The serum level of L-PGDS, as determined by a sandwich ELISA, was 58.1 ± 2.2, 62.0 ± 1.8 and 80.6 ± 2.6 μg/dl for patients with no stenotic lesion (N, n = 241), single-vessel coronary artery disease (S, n = 351), and multi-vessel coronary artery disease (M, n = 421), respectively (N vs. S; P < 0.001, S vs. M; P < 0.01, N vs. M; P < 0.001). Multiple regression analysis indicated that the most powerful independent predictor of the coronary severity score (Gensini Score) was the L-PGDS level (R = 0.55, P < 0.0001). The serum L-PGDS level is suitable to evaluate the severity of coronary artery disease. The measurement of serum L-PGDS can be a strategy for screening of stable coronary artery disease prior to coronary angiography.

Original languageEnglish
Pages (from-to)385-391
Number of pages7
JournalAtherosclerosis
Volume201
Issue number2
DOIs
Publication statusPublished - 01-12-2008

Fingerprint

prostaglandin R2 D-isomerase
Lipocalins
Coronary Artery Disease
Biomarkers
Serum
Coronary Angiography
Prostaglandin D2
Atherosclerotic Plaques
Multicenter Studies
Coronary Vessels
Angiography
Enzyme-Linked Immunosorbent Assay
Regression Analysis

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

Inoue, Teruo ; Eguchi, Yutaka ; Matsumoto, Tetsuya ; Kijima, Yoshiyuki ; Kato, Yoji ; Ozaki, Yukio ; Waseda, Katsuhisa ; Oda, Hiroshi ; Seiki, Kosuke ; Node, Koichi ; Urade, Yoshihiro. / Lipocalin-type prostaglandin D synthase is a powerful biomarker for severity of stable coronary artery disease. In: Atherosclerosis. 2008 ; Vol. 201, No. 2. pp. 385-391.
@article{e618dacb0cca49f591d89061f632ffb7,
title = "Lipocalin-type prostaglandin D synthase is a powerful biomarker for severity of stable coronary artery disease",
abstract = "Lipocalin-type prostaglandin D synthase (L-PGDS), which is responsible for the biosynthesis of prostaglandin (PG) D2, has been found to be present in the atherosclerotic plaque of the human coronary artery and also to be detectable in human serum. This multicenter cooperative study was designed to establish the diagnostic value of measuring serum L-PGDS for coronary artery disease. The study included 1013 consecutive patients suspected of having stable coronary artery disease who underwent diagnostic coronary angiography. Peripheral blood was collected prior to angiography. The serum level of L-PGDS, as determined by a sandwich ELISA, was 58.1 ± 2.2, 62.0 ± 1.8 and 80.6 ± 2.6 μg/dl for patients with no stenotic lesion (N, n = 241), single-vessel coronary artery disease (S, n = 351), and multi-vessel coronary artery disease (M, n = 421), respectively (N vs. S; P < 0.001, S vs. M; P < 0.01, N vs. M; P < 0.001). Multiple regression analysis indicated that the most powerful independent predictor of the coronary severity score (Gensini Score) was the L-PGDS level (R = 0.55, P < 0.0001). The serum L-PGDS level is suitable to evaluate the severity of coronary artery disease. The measurement of serum L-PGDS can be a strategy for screening of stable coronary artery disease prior to coronary angiography.",
author = "Teruo Inoue and Yutaka Eguchi and Tetsuya Matsumoto and Yoshiyuki Kijima and Yoji Kato and Yukio Ozaki and Katsuhisa Waseda and Hiroshi Oda and Kosuke Seiki and Koichi Node and Yoshihiro Urade",
year = "2008",
month = "12",
day = "1",
doi = "10.1016/j.atherosclerosis.2008.03.010",
language = "English",
volume = "201",
pages = "385--391",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

Inoue, T, Eguchi, Y, Matsumoto, T, Kijima, Y, Kato, Y, Ozaki, Y, Waseda, K, Oda, H, Seiki, K, Node, K & Urade, Y 2008, 'Lipocalin-type prostaglandin D synthase is a powerful biomarker for severity of stable coronary artery disease', Atherosclerosis, vol. 201, no. 2, pp. 385-391. https://doi.org/10.1016/j.atherosclerosis.2008.03.010

Lipocalin-type prostaglandin D synthase is a powerful biomarker for severity of stable coronary artery disease. / Inoue, Teruo; Eguchi, Yutaka; Matsumoto, Tetsuya; Kijima, Yoshiyuki; Kato, Yoji; Ozaki, Yukio; Waseda, Katsuhisa; Oda, Hiroshi; Seiki, Kosuke; Node, Koichi; Urade, Yoshihiro.

In: Atherosclerosis, Vol. 201, No. 2, 01.12.2008, p. 385-391.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Lipocalin-type prostaglandin D synthase is a powerful biomarker for severity of stable coronary artery disease

AU - Inoue, Teruo

AU - Eguchi, Yutaka

AU - Matsumoto, Tetsuya

AU - Kijima, Yoshiyuki

AU - Kato, Yoji

AU - Ozaki, Yukio

AU - Waseda, Katsuhisa

AU - Oda, Hiroshi

AU - Seiki, Kosuke

AU - Node, Koichi

AU - Urade, Yoshihiro

PY - 2008/12/1

Y1 - 2008/12/1

N2 - Lipocalin-type prostaglandin D synthase (L-PGDS), which is responsible for the biosynthesis of prostaglandin (PG) D2, has been found to be present in the atherosclerotic plaque of the human coronary artery and also to be detectable in human serum. This multicenter cooperative study was designed to establish the diagnostic value of measuring serum L-PGDS for coronary artery disease. The study included 1013 consecutive patients suspected of having stable coronary artery disease who underwent diagnostic coronary angiography. Peripheral blood was collected prior to angiography. The serum level of L-PGDS, as determined by a sandwich ELISA, was 58.1 ± 2.2, 62.0 ± 1.8 and 80.6 ± 2.6 μg/dl for patients with no stenotic lesion (N, n = 241), single-vessel coronary artery disease (S, n = 351), and multi-vessel coronary artery disease (M, n = 421), respectively (N vs. S; P < 0.001, S vs. M; P < 0.01, N vs. M; P < 0.001). Multiple regression analysis indicated that the most powerful independent predictor of the coronary severity score (Gensini Score) was the L-PGDS level (R = 0.55, P < 0.0001). The serum L-PGDS level is suitable to evaluate the severity of coronary artery disease. The measurement of serum L-PGDS can be a strategy for screening of stable coronary artery disease prior to coronary angiography.

AB - Lipocalin-type prostaglandin D synthase (L-PGDS), which is responsible for the biosynthesis of prostaglandin (PG) D2, has been found to be present in the atherosclerotic plaque of the human coronary artery and also to be detectable in human serum. This multicenter cooperative study was designed to establish the diagnostic value of measuring serum L-PGDS for coronary artery disease. The study included 1013 consecutive patients suspected of having stable coronary artery disease who underwent diagnostic coronary angiography. Peripheral blood was collected prior to angiography. The serum level of L-PGDS, as determined by a sandwich ELISA, was 58.1 ± 2.2, 62.0 ± 1.8 and 80.6 ± 2.6 μg/dl for patients with no stenotic lesion (N, n = 241), single-vessel coronary artery disease (S, n = 351), and multi-vessel coronary artery disease (M, n = 421), respectively (N vs. S; P < 0.001, S vs. M; P < 0.01, N vs. M; P < 0.001). Multiple regression analysis indicated that the most powerful independent predictor of the coronary severity score (Gensini Score) was the L-PGDS level (R = 0.55, P < 0.0001). The serum L-PGDS level is suitable to evaluate the severity of coronary artery disease. The measurement of serum L-PGDS can be a strategy for screening of stable coronary artery disease prior to coronary angiography.

UR - http://www.scopus.com/inward/record.url?scp=54249093581&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54249093581&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2008.03.010

DO - 10.1016/j.atherosclerosis.2008.03.010

M3 - Article

C2 - 18436228

AN - SCOPUS:54249093581

VL - 201

SP - 385

EP - 391

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 2

ER -